RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition
BRCA1/2 mutations play a predictive role in ovarian cancer risk evaluation. Moreover , patients are today being tested for BRCA1/2 mutations to select a tailored therapy too , because they could benefit from a treatment with PARP inhibitors (PARPi).Therefore in ovarian carcinomas (OCs), BRCA1/2 mutation testing is an important step in planning the correct therapeutic strategy in association with chemotherapy and anti VEGF agents.